Review
Biochemistry & Molecular Biology
Fabio Scirocchi, Lidia Strigari, Alessandra Di Filippo, Chiara Napoletano, Angelica Pace, Hassan Rahimi, Andrea Botticelli, Aurelia Rughetti, Marianna Nuti, Ilaria Grazia Zizzari
Summary: This study investigates the correlation between soluble programmed death ligand-1 (sPD-L1) and survival in cancer patients undergoing immunotherapy. The results show that high levels of sPD-L1 are associated with worse overall survival and progression-free survival in cancer patients treated with immunotherapy. Specifically, in non-small cell lung cancer patients, higher levels of sPD-L1 are correlated with poorer survival. sPD-L1 could serve as a non-invasive biomarker that is easily measurable in the blood, helping to select cancer patients before immunotherapy and improve treatment efficacy while avoiding unnecessary treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Jun-Shuai Xue, Hui Liu, Guang-Xiao Meng, Zi-Niu Ding, Lun-Jie Yan, Sheng-Yu Yao, Hai-Chao Li, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
Summary: This study found that in hepatocellular carcinoma (HCC), high levels of sPD-L1 are associated with poorer overall survival and disease-free survival, while levels of sPD-1 are not significantly correlated with prognosis.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Oncology
Kiyohiro Ando, Kazuyuki Hamada, Midori Shida, Ryotaro Ohkuma, Yutaro Kubota, Atsushi Horiike, Hiroto Matsui, Tomoyuki Ishiguro, Yuya Hirasawa, Hirotsugu Ariizumi, Makoto Watanabe, Rie Onoue, Junji Tsurutani, Kiyoshi Yoshimura, Takuya Tsunoda, Shinichi Kobayashi, Satoshi Wada
Summary: The study investigated the prognostic impact of pretreatment PD-L1 expression levels in PBMC subsets in patients receiving anti-PD-1 blockade therapy. It was found that an increase in PD-L1 expression levels on CD14(+)monocytes was significantly associated with overall survival, suggesting a potential predictive role of PBMC in patients treated with immune checkpoint inhibitors.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Se Jun Park, Ju Yeon Park, Kabsoo Shin, Tae Ho Hong, MyungAh Lee, Younghoon Kim, In-Ho Kim
Summary: This study investigated the correlation between circulating exosomal PD-L1 (exoPD-L1) and PD-L1 expression in tumor tissue, as well as the impact on survival outcomes in patients with advanced PDAC. The results showed that the levels of exoPD-L1 were higher in patients with metastatic pancreatic cancer compared to those with locally advanced disease, and were also higher in patients with positive PD-L1 expression. Higher levels of exoPD-L1 were associated with worse survival outcomes.
Article
Oncology
Hanqun Zhang, Shisheng Tan, Chunju Fang, Qi Zhang, Xue Cao, Yuncong Liu
Summary: This study explores the role of PD-1/PD-L1 in the evaluation of concurrent chemoradiotherapy efficacy and prognosis in cervical cancer patients. The results suggest that PD-1/PD-L1 may be a potential indicator for evaluating the efficacy and prognosis of CCRT in cervical cancer, providing potential targets for its treatment.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Wen Wen, Yong Zhang, Hua Zhang, Yingshuang Chen
Summary: PD-L1/PD-1 inhibitors have shown effective and tolerable outcomes in advanced hepatocellular carcinoma patients. Additionally, the combination of PD-L1/PD-1 inhibitors with anti-VEGF agents leads to more clinical improvements compared to monotherapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Jun Xu, Jianguo Zhao, Jianfang Wang, Caiping Sun, Xiaoling Zhu
Summary: This meta-analysis suggests that a higher pretreatment LDH level is significantly associated with worse overall survival and shorter progression-free survival in melanoma patients receiving anti-PD1/PD-L1 monotherapy.
Article
Plant Sciences
Zi-Xuan Gao, Zhan-Sheng Zhang, Jia Qin, Ming -Zhu Zhang, Jin-Lan Cao, Ying-Ying Li, Meng-Qing Wang, Dong Fang, Song-Qiang Xie
Summary: This study evaluated the antitumor effects of aucubin on hepatocellular carcinoma (HCC) and investigated its synergistic effects with cisplatin. The results showed that aucubin inhibited tumor growth and suppressed PD-L1 expression through the Akt/beta-catenin signaling pathway. Aucubin also enhanced the antitumor activity of cisplatin by blocking PD-L1 expression.
Article
Oncology
Panpan Kong, Huan Yang, Qing Tong, Xiaogang Dong, Mamumaimaitijiang-Abula Yi, Dong Yan
Summary: PD-L1, CD86, and CD206 are involved in the occurrence and development of liver cancer and immune regulation, suggesting their potential role as biomarkers and therapeutic targets for prognosis assessment of liver cancer.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Min Deng, Shao-Hua Li, Xu Fu, Xiao-Peng Yan, Jun Chen, Yu-Dong Qiu, Rong-Ping Guo
Summary: The study revealed a correlation between high expression of PD-L1 in tumors of ICC patients and poor overall survival, while the number of CD8+ T cells was associated with poor overall survival and disease-free survival.
CANCER CELL INTERNATIONAL
(2021)
Article
Oncology
Shengxiang Ren, Jifeng Feng, Shenglin Ma, HuaJun Chen, Zhiyong Ma, Cheng Huang, Li Zhang, Jianxing He, Changli Wang, Jianying Zhou, Pongwut Danchaivijtr, Chin-Chou Wang, Ihor Vynnychenko, Kai Wang, Francisco Orlandi, Virote Sriuranpong, Ben Li, Jun Ge, Thao Dang, Caicun Zhou
Summary: KEYNOTE-033 is a multicountry, open-label, phase 3 study that compared the efficacy of pembrolizumab and docetaxel in mainland China, in previously treated, PD-L1-positive, advanced NSCLC patients. The study showed that pembrolizumab improved overall survival compared to docetaxel in patients with PD-L1 TPS >= 1%. However, statistical significance was not reached in patients with PD-L1 TPS >= 50%. The performance of pembrolizumab in treating NSCLC is consistent with previous observations.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
Xinfang Yu, Wei Li, Ken H. Young, Yong Li
Summary: PD-L1 is a classic immune checkpoint molecule with its expression regulated by posttranslational modifications (PTMs) that play vital roles in controlling PD-L1 expression, cellular trafficking, and antitumor immune response.
Article
Biochemistry & Molecular Biology
Adam Szeles, Petra Terezia Kovacs, Anita Csizmarik, Melinda Varadi, Peter Riesz, Tamas Fazekas, Szilard Vancsa, Peter Hegyi, Csilla Olah, Stephan Tschirdewahn, Christopher Darr, Ulrich Krafft, Viktor Grunwald, Boris Hadaschik, Orsolya Horvath, Peter Nyirady, Tibor Szarvas
Summary: This study aimed to assess the prognostic relevance of soluble serum PD-L1 in upper tract urothelial carcinoma (UTUC) patients. The study found that high preoperative sPD-L1 levels were correlated with higher pathological tumor stage, grade and the presence of metastasis, and were associated with shorter survival in surgically and chemotherapy-treated UTUC patients. The study also observed a characteristic increase in serum PD-L1 levels after 3 months of anti-PD-L1 therapy in UTUC patients. Based on these results, sPD-L1 is a promising prognostic biomarker in UTUC.
Article
Oncology
Pei Huang, Wei Hu, Ying Zhu, Yushen Wu, Huapeng Lin
Summary: This meta-analysis found that high levels of sPD-L1 in cancer patients were associated with worse survival prognosis, suggesting that sPD-L1 may serve as a potential prognostic, non-invasive, and dynamic monitoring biomarker for cancers in the future.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Liying Yang, Wei Zhang, Jujie Sun, Guanqun Yang, Siqi Cai, Fenghao Sun, Ligang Xing, Xiaorong Sun
Summary: This study investigated the relationship between the spatial interaction of PD-L1-positive tumor cells and T cells with specific functions and the recurrence of NSCLC, and optimized prognostic stratification. It was found that the number of PD-L1-positive tumor cells was higher in the tumor center compared to the invasion margin, while the number of T cells, especially PD-1-positive CD8 T cells, was lower. The proximity between CD8 T cells and PD-L1-positive tumor cells was closer, especially for exhausted CD8 T cells. The density and percentage of PD-1-positive CD4 T cells interacting with PD-L1-positive tumor cells were associated with recurrence, with increasing risk. Patients with low PD-1-positive CD4 count and high PD-1-positive CD4 density had a significantly higher risk of recurrence. The spatial proximity assessment of PD-1/PD-L1 contributes to a better understanding of tumor immune escape and provides prognostic information for NSCLC patients.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
